Gustave Roussy shared on X:
“Gustave Roussy at ESMO26
A fascinating discussion at ESMO presidential session with Prof. Benjamin Besse, putting the Krascendo1 results of divarasib, a next-generation KRAS G12C inhibitor, into perspective in NSCLC.
A key question emerged: when PFS is the primary endpoint, how design trial should be balanced with patients’ access to therapeutic innovation?”
You can also read: Krascendo 1 Phase III: Divarasib Significantly Improves Overall Survival and Progression-Free Survival Versus Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC
